460
H. Jin
215. Povsic TJ VJ, Kasprzak JD et al. A randomized, partially-blinded, multi-center, activecontrolled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of
the REG1 anticoagulation system compared with unfractionated heparin or low molecular
weight heparin in subjects with acute coronary syndromes: pri-mary results of the RADAR
randomized clinical trial. In: The 60th Annual Scientific Session of the American College of
Cardiology: New Orleans, LA, USA, 2–5 April 2011
216. Lincoff AM, Mehran R, Povsic TJ, Zelenkofske SL, Huang Z, Armstrong PW, Steg PG,
Bode C, Cohen MG, Buller C, Laanmets P, Valgimigli M, Marandi T, Fridrich V, Cantor WJ,
Merkely B, Lopez-Sendon J, Cornel JH, Kasprzak JD, Aschermann M, Guetta V, Morais J,
Sinnaeve PR, Huber K, Stables R, Sellers MA, Borgman M, Glenn L, Levinson AI, Lopes RD,
Hasselblad V, Becker RC, Alexander JH (2016) Effect of the REG1 anticoagulation system
versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI):
a randomised clinical trial. Lancet 387(10016):349–356. https://doi.org/10.1016/s0140-673
6(15)00515-2
217. Ganson NJ, Povsic TJ, Sullenger BA, Alexander JH, Zelenkofske SL, Sailstad JM, Rusconi CP,
Hershfield MS (2016) Pre-existing anti-polyethylene glycol antibody linked to first-exposure
allergic reactions to pegnivacogin, a PEGylated RNA aptamer. J Allergy Clin Immunol
137(5):1610–1613.e1617. https://doi.org/10.1016/j.jaci.2015.10.034
218. Povsic TJ, Lawrence MG, Lincoff AM, Mehran R, Rusconi CP, Zelenkofske SL, Huang
Z, Sailstad J, Armstrong PW, Steg PG, Bode C, Becker RC, Alexander JH, Adkinson NF,
Levinson AI (2016) Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. J Allergy Clin Immunol
138(6):1712–1715. https://doi.org/10.1016/j.jaci.2016.04.058
219. Alzheimer’s disease facts and figures (2016) Alzheimers Dement 12(4):459–509. https://doi.
org/10.1016/j.jalz.2016.03.001
220. Alzheimer’s disease facts and figures (2020) Alzheimers Dement. https://doi.org/10.1002/alz.
12068
221. Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, Abbott RD, Savica R, Van Den
Eeden SK, Willis AW, Tanner CM (2018) Prevalence of Parkinson’s disease across North
America. NPJ Parkinsons Dis 4:21. https://doi.org/10.1038/s41531-018-0058-0
222. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C (2014) Potential for primary prevention
of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol 13(8):788–794.
https://doi.org/10.1016/s1474-4422(14)70136-x
223. Zhu L, Zhang J, Wang F, Wang Y, Lu L, Feng C, Xu Z, Zhang W (2016) Selective
amyloid β oligomer assay based on abasic site-containing molecular beacon and enzyme-free
amplification. Biosens Bioelectron 78:206–212. https://doi.org/10.1016/j.bios.2015.11.048
224. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer’s disease.
Nat Rev Neurosci 8(7):499–509. https://doi.org/10.1038/nrn2168
225. He Z, Guo JL, McBride JD, Narasimhan S, Kim H, Changolkar L, Zhang B, Gathagan RJ,
Yue C, Dengler C, Stieber A, Nitla M, Coulter DA, Abel T, Brunden KR, Trojanowski JQ,
Lee VM (2018) Amyloid-β plaques enhance Alzheimer’s brain tau-seeded pathologies by
facilitating neuritic plaque tau aggregation. Nat Med 24(1):29–38. https://doi.org/10.1038/
nm.4443
226. Ylera F, Lurz R, Erdmann VA, Fürste JP (2002) Selection of RNA aptamers to the Alzheimer’s
disease amyloid peptide. Biochem Biophys Res Commun 290(5):1583–1588. https://doi.org/
10.1006/bbrc.2002.6354
227. Farrar CT, William CM, Hudry E, Hashimoto T, Hyman BT (2014) RNA aptamer probes as
optical imaging agents for the detection of amyloid plaques. PLoS ONE 9(2):e89901. https://
doi.org/10.1371/journal.pone.0089901
228. Tsukakoshi K, Abe K, Sode K, Ikebukuro K (2012) Selection of DNA aptamers that recognize
α-synuclein oligomers using a competitive screening method. Anal Chem 84(13):5542–5547.
https://doi.org/10.1021/ac300330g
229. Chan HN, Xu D, Ho SL, He D, Wong MS, Li HW (2019) Highly sensitive quantification of
Alzheimer’s disease biomarkers by aptamer-assisted amplification. Theranostics 9(10):2939–
2949. https://doi.org/10.7150/thno.29232
H. Jin
215. Povsic TJ VJ, Kasprzak JD et al. A randomized, partially-blinded, multi-center, activecontrolled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of
the REG1 anticoagulation system compared with unfractionated heparin or low molecular
weight heparin in subjects with acute coronary syndromes: pri-mary results of the RADAR
randomized clinical trial. In: The 60th Annual Scientific Session of the American College of
Cardiology: New Orleans, LA, USA, 2–5 April 2011
216. Lincoff AM, Mehran R, Povsic TJ, Zelenkofske SL, Huang Z, Armstrong PW, Steg PG,
Bode C, Cohen MG, Buller C, Laanmets P, Valgimigli M, Marandi T, Fridrich V, Cantor WJ,
Merkely B, Lopez-Sendon J, Cornel JH, Kasprzak JD, Aschermann M, Guetta V, Morais J,
Sinnaeve PR, Huber K, Stables R, Sellers MA, Borgman M, Glenn L, Levinson AI, Lopes RD,
Hasselblad V, Becker RC, Alexander JH (2016) Effect of the REG1 anticoagulation system
versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI):
a randomised clinical trial. Lancet 387(10016):349–356. https://doi.org/10.1016/s0140-673
6(15)00515-2
217. Ganson NJ, Povsic TJ, Sullenger BA, Alexander JH, Zelenkofske SL, Sailstad JM, Rusconi CP,
Hershfield MS (2016) Pre-existing anti-polyethylene glycol antibody linked to first-exposure
allergic reactions to pegnivacogin, a PEGylated RNA aptamer. J Allergy Clin Immunol
137(5):1610–1613.e1617. https://doi.org/10.1016/j.jaci.2015.10.034
218. Povsic TJ, Lawrence MG, Lincoff AM, Mehran R, Rusconi CP, Zelenkofske SL, Huang
Z, Sailstad J, Armstrong PW, Steg PG, Bode C, Becker RC, Alexander JH, Adkinson NF,
Levinson AI (2016) Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. J Allergy Clin Immunol
138(6):1712–1715. https://doi.org/10.1016/j.jaci.2016.04.058
219. Alzheimer’s disease facts and figures (2016) Alzheimers Dement 12(4):459–509. https://doi.
org/10.1016/j.jalz.2016.03.001
220. Alzheimer’s disease facts and figures (2020) Alzheimers Dement. https://doi.org/10.1002/alz.
12068
221. Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, Abbott RD, Savica R, Van Den
Eeden SK, Willis AW, Tanner CM (2018) Prevalence of Parkinson’s disease across North
America. NPJ Parkinsons Dis 4:21. https://doi.org/10.1038/s41531-018-0058-0
222. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C (2014) Potential for primary prevention
of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol 13(8):788–794.
https://doi.org/10.1016/s1474-4422(14)70136-x
223. Zhu L, Zhang J, Wang F, Wang Y, Lu L, Feng C, Xu Z, Zhang W (2016) Selective
amyloid β oligomer assay based on abasic site-containing molecular beacon and enzyme-free
amplification. Biosens Bioelectron 78:206–212. https://doi.org/10.1016/j.bios.2015.11.048
224. LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer’s disease.
Nat Rev Neurosci 8(7):499–509. https://doi.org/10.1038/nrn2168
225. He Z, Guo JL, McBride JD, Narasimhan S, Kim H, Changolkar L, Zhang B, Gathagan RJ,
Yue C, Dengler C, Stieber A, Nitla M, Coulter DA, Abel T, Brunden KR, Trojanowski JQ,
Lee VM (2018) Amyloid-β plaques enhance Alzheimer’s brain tau-seeded pathologies by
facilitating neuritic plaque tau aggregation. Nat Med 24(1):29–38. https://doi.org/10.1038/
nm.4443
226. Ylera F, Lurz R, Erdmann VA, Fürste JP (2002) Selection of RNA aptamers to the Alzheimer’s
disease amyloid peptide. Biochem Biophys Res Commun 290(5):1583–1588. https://doi.org/
10.1006/bbrc.2002.6354
227. Farrar CT, William CM, Hudry E, Hashimoto T, Hyman BT (2014) RNA aptamer probes as
optical imaging agents for the detection of amyloid plaques. PLoS ONE 9(2):e89901. https://
doi.org/10.1371/journal.pone.0089901
228. Tsukakoshi K, Abe K, Sode K, Ikebukuro K (2012) Selection of DNA aptamers that recognize
α-synuclein oligomers using a competitive screening method. Anal Chem 84(13):5542–5547.
https://doi.org/10.1021/ac300330g
229. Chan HN, Xu D, Ho SL, He D, Wong MS, Li HW (2019) Highly sensitive quantification of
Alzheimer’s disease biomarkers by aptamer-assisted amplification. Theranostics 9(10):2939–
2949. https://doi.org/10.7150/thno.29232